Wave Life Sciences 2026 strategic priorities were outlined by the company at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, where executives provided an overview of its roadmap for advancing RNA medicines in 2026. According to the press release from Wave Life Sciences Ltd., the company will focus on accelerating clinical development of its WVE-007 INHBE siRNA candidate for obesity and rapidly advancing its RNA editing portfolio into late-stage clinical and regulatory milestones.
Wave said it plans to initiate a Phase 2a multidose portion of the ongoing INLIGHT clinical trial evaluating WVE-007 in individuals living with obesity and higher BMI in the first half of 2026, with additional trial formats to follow later in the year.
Priorities in RNA editing and broader pipeline
The company highlighted progress in its RNA editing programmes, including continued development of WVE-006 for alpha-1 antitrypsin deficiency and planned CTA filings for WVE-008 targeting PNPLA3 I148M liver disease in the United States and Europe during 2026. Wave also noted that its RNA medicines platform has demonstrated differentiated profiles that support future combination and bifunctional constructs, potentially broadening the therapeutic reach of its technology.
